

METABASIS THERAPEUTICS INC  
Form 8-K  
January 14, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Form 8-K**

**Current Report Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 13, 2009**

---

**Metabasis Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**000-50785**  
(Commission File Number)

**33-0753322**  
(I.R.S. Employer  
Identification No.)

**11119 North Torrey Pines Road**  
**La Jolla, California**  
(Address of principal executive offices)

**92037**  
(Zip Code)

Registrant's telephone number, including area code: **(858) 587-2770**

**Not Applicable.**

Edgar Filing: METABASIS THERAPEUTICS INC - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On January 13, 2009, Mark D. Erion, Ph.D., our President, Chief Executive Officer and Chief Scientific Officer, presented a corporate overview during the J.P. Morgan's 27<sup>th</sup> Annual Healthcare Conference in San Francisco, California. As part of the presentation, Alan Garber, M.D., Ph.D., presented an overview of the results of our Phase 2a clinical study on MB07803, a product candidate for the treatment of type 2 diabetes. A copy of the presentation materials is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

Number	Description
99.1	Presentation of Metabasis Therapeutics, Inc. dated January 13, 2009.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**METABASIS THERAPEUTICS, INC.**

By: */s/ Mark D. Erion, Ph.D.*  
*Mark D. Erion, Ph.D.*  
*President, Chief Executive Officer and Chief*  
*Scientific Officer*

Date: January 14, 2009

**INDEX TO EXHIBITS**

<b>Number</b>	<b>Description</b>
99.1	Presentation of Metabasis Therapeutics, Inc. dated January 13, 2009.